What concerns me most about the financing is why are we coming down to the final hour?

The maturity date has always been know and again through past updates, I believe I can recall DM indicating (I can’t quote the exact words) but the messaging or my sediment, at the time, was that it was a non-issue and it was being dealt with. 

In my opinion, when DM spoke those words, FA or FDA should never been a contingency of funding.  If it was, I as a CEO, would have been looking at securing additional funding long, long ago through all avenues available….Now all this should/could/would be mute if we had some update/communication – which is driving the speculation!! 

So back to my question – why has RVX not put the LOC/financing issue behind us?   Why does it need to come at the final hour?  

On a side note:  I had posted this on the Zenith site a while back but in case you missed it; 

June 20, 2017 

BRIEF-Shenzhen Hepalink Pharmaceutical to apply for comprehensive credit line of 270 mln yuan     (approx 51 Million CND)

https://www.reuters.com/article/brief-shenzhen-hepalink-pharmaceutical-t-idUSL3N1JI1OZ

I wonder why they would need a loan.

DYODD 

Long.